VSTM · Verastem, Inc. · Investor Relations
$9.34
+0.72 (+8.35%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, given the risks associated with these potential strategic or financing opportunities, they are not deemed probable for purposes of the going concern assessment and do not alleviate the substantial doubt about our ability to continue as a going concern. There can be no assurance that we will be able to generate sufficient net product revenues or obtain additional capital on favorable terms or at all.”View the 10-Q filed Aug 6, 2026
Market Cap
$806.01M
Shares
90.56M
Volume · Oct 20
3.96M
Avg daily vol (3M)
3.07M
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-10-14 | Verastem Oncology VS-7375 R&D Update | Event |
| 2026-09-14 | H.C. Wainwright Annual Global Investment Conference | Conference |
| 2026-09-10 | Cantor Global Healthcare Conference | Conference |
| 2026-08-06 | Verastem Oncology 2Q26 Earnings Call | Earnings call |
| 2026-06-23 | Verastem Oncology VS-7375 TARGET-D Conference Call | Conference |
| 2026-06-03 | Jefferies Global Healthcare Conference | Conference |
| 2026-05-20 | RBC Global Healthcare Conference | Conference |
| 2026-05-19 | HCW 4th Annual BioConnect Investor Conference | Conference |
| 2026-05-07 | Verastem Oncology 1Q26 Earnings Call | Earnings call |
| 2026-03-04 | Verastem Oncology 4Q/FY25 Earnings Call | Earnings call |
| 2026-02-11 | Guggenheim Emerging Outlook: Biotech Summit 2026 | Event |
| 2025-11-04 | Verastem Oncology 3Q25 Earnings Call | Earnings call |
| 2025-08-07 | Verastem Oncology 2Q25 Earnings Call | Earnings call |
Source: https://investor.verastem.com/
Key facts
CIK
1526119
CUSIP
92337C203
13F (30d)
11 filings
11 filers
Visit website
Investor relations